Primary Immuno-Deficiencies Affecting Specific Stages of the Immune Response
Project Number5P01AI076210-03
Contact PI/Project LeaderTERHORST, CORNELIS P
Awardee OrganizationBETH ISRAEL DEACONESS MEDICAL CENTER
Description
Abstract Text
DESCRIPTION (provided by applicant): This revised application for our new Program Project Grant brings together a group of investigators who are experts in the areas of molecular and cellular immunology and human and mouse genetics. We propose to study the role of single genes in the pathogenesis of X-linked Lymphoproliferative syndrome (XLP), Common variable immunodeficiency (CVID), Omenn syndrome and Severe Combined Immunodeficiencies (SCID) in an application, entitled: "Primary Immunodeficiencies Affecting Specific Stages of the Adaptive Immune Response" Because of successful preliminary analyses of patient materials, exciting findings in genetically altered mice, this application seeks to define how mutations in the SH2D1A, SH2D1B/C, TACI, RAG-1/2, DNA Ligase IV or Cernunnos genes affect T and B cell development and T cell dependent and/or T cell-independent immunoglobulin responses. We will use our recently acquired insights into the causes of these diseases in the following four interlinked projects and an Administrative Core: Project #1 Role of the SAP (SH2D1A) gene in T cell-dependent antibody responses. Cox Terhorst, Beth Israel Deaconess Medical Center. Project #2 Role of in TACI mutations in Common Variable Immunodeficiency Raif Geha, Children's Hospital of Boston. Project #3 Gene knock-in models for Omenn syndrome and leaky SCID. LuigiNotarangelo, Children's Hospital of Boston. Project #4 Mouse Models of Severe Combined Immunodeficiencies. Fred Alt, Children's Hospital of Boston. Core A Administrative Core Cox Terhorst, Beth Israel Deaconess Medical Center. The outcomes of proposed studies should lead to better understanding of the complex and often alternate disease manifestations that are caused by mutations in a single gene. The results of these studies should suggest therapeutic strategies that can be applied to these PID patients and may unravel molecular and cellular mechanisms that are generally involved in immune dysregulation, autoimmunity and cancer.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
071723621
UEI
C1CPANL3EWK4
Project Start Date
05-July-2009
Project End Date
30-June-2014
Budget Start Date
01-July-2011
Budget End Date
30-June-2012
Project Funding Information for 2011
Total Funding
$1,808,883
Direct Costs
$1,604,412
Indirect Costs
$204,471
Year
Funding IC
FY Total Cost by IC
2011
National Institute of Allergy and Infectious Diseases
$1,808,883
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P01AI076210-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P01AI076210-03
Patents
No Patents information available for 5P01AI076210-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P01AI076210-03
Clinical Studies
No Clinical Studies information available for 5P01AI076210-03
News and More
Related News Releases
No news release information available for 5P01AI076210-03
History
No Historical information available for 5P01AI076210-03
Similar Projects
No Similar Projects information available for 5P01AI076210-03